Indoco Remedies

INDOCO.NS

Mumbai, India· Est. 1947

indoco.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

INDOCO.NS · Stock Price

INR 250.65+9.49 (+3.94%)

Market Cap: $222.4M

Historical price data

Market Cap: $222.4MPatents: 5Founded: 1947Employees: ~6000HQ: Mumbai, India

Sector Ranking#87 in Small Molecule Drugs

Overview

Founded in 1947, Indoco Remedies has evolved from a trading concern into a $15+ billion market cap pharmaceutical enterprise with a mission to deliver high-quality, affordable medicines globally. Its core strategy is built on vertical integration, combining API synthesis with sophisticated formulation development in complex generics, particularly sterile injectables, ophthalmics, and oral solutions. Recent achievements include multiple USFDA ANDA approvals, successful regulatory inspections with zero observations, and strategic expansion into key international markets like the US and Europe through partnerships and acquisitions.

CNS / EpilepsyCardiovascularAnti-infectivesOphthalmologyMetabolic Disorders

Technology Platform

A fully integrated platform combining advanced API synthesis with sophisticated development and manufacturing of complex generic dosage forms, particularly sterile injectables, ophthalmic solutions, and oral suspensions.

Funding History

Total raised:$15M

IPO$15MUndisclosedSep 30, 2004

FDA Approved Drugs

RIVAROXABANANDAAug 11, 2025

VARENICLINE TARTRATEANDAOct 29, 2024

CETIRIZINE HYDROCHLORIDEANDAOct 3, 2024

Opportunities

The primary opportunities lie in capitalizing on recent USFDA approvals for complex generics like Rivaroxaban, expanding the API merchant business post-successful USFDA inspection, and leveraging the EU GMP certification to grow sterile product sales in regulated markets.

The strategic acquisition in the US provides a direct commercial pathway for future products.

Risk Factors

Key risks include sustained pricing pressure in the generics market, potential regulatory setbacks at manufacturing facilities despite a strong track record, and execution challenges in integrating acquisitions and scaling up commercial operations in competitive international markets.

Competitive Landscape

Indoco competes through differentiation in complex generics rather than scale, facing off against large Indian pharma peers domestically and global generic firms internationally. Its competitive edge is its technical expertise in sterile dosage forms and APIs, which creates higher barriers to entry and more stable pricing in its chosen segments.